Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

(2013) T. Kadowaki et al.   DIABETES OBESITY & METABOLISM

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

(2012) T. Eto et al.   DIABETES OBESITY & METABOLISM

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

(2010) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP-4 inhibitors and sulphonylureas

(2009) B. Gallwitz et al.   DIABETES OBESITY & METABOLISM

Diabetes in Japan: a review of disease burden and approaches to treatment

(2009) Susan E. Neville et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

The cAMP Sensor Epac2 Is a Direct Target of Antidiabetic Sulfonylurea Drugs

(2009) C.-L. Zhang et al.   SCIENCE